75エピソード

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • 科学

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Elizabeth Yeu, MD - Navigating Evolving Treatment Approaches to Dry Eye: Halting Progression and Easing the Burden on Quality of Life

    Elizabeth Yeu, MD - Navigating Evolving Treatment Approaches to Dry Eye: Halting Progression and Easing the Burden on Quality of Life

    Go online to PeerView.com/UHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses the impact of dry eye disease and current and emerging treatment approaches for patients with dry eye disease. Upon completion of this activity, participants should be better able to: Recognize the impact of dry eye on the quality of life of patients, particularly if left untreated, Identify patients with dry eye according to signs, symptoms, and the latest diagnostic criteria, Summarize the latest clinical data on efficacy and safety of novel and emerging therapies for dry eye, Develop treatment plans for patients with dry eye according to disease severity and the latest clinical evidence of available therapeutic agents

    • 29分
    • video
    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Go online to PeerView.com/GZX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in hepatology discusses current and emerging strategies to diagnose, treat, and manage patients with nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Correctly diagnose and stage nonalcoholic fatty liver disease (NAFLD), distinguishing the subset of patients with NASH for disease monitoring and prognostication, Apply best practices in the management of patients with NASH based on evolving data on lifestyle modification and medical treatment, Evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH

    • 27分
    • video
    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs

    • 30分
    • video
    Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC - Demystifying the Real-World Evidence in Atrial Fibrillation: A Comparative Look at the Direct Oral Anticoagulants for Reducing the Risk of Stroke Among Patients With Nonvalvular Atrial Fibrillation

    Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC - Demystifying the Real-World Evidence in Atrial Fibrillation: A Comparative Look at the Direct Oral Anticoagulants for Reducing the Risk of Stroke Among Patients With Nonvalvular Atrial Fibrillation

    Go online to PeerView.com/NNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hospital and vascular medicine discusses how real-world data enhance the data from randomized clinical trials on direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) and offers insight on applying evidence from both real-world studies and randomized clinical trials to improve patient care. Upon completion of this activity, participants will be able to: Identify the role of real-world data and evidence in augmenting the efficacy and safety data that have been collected as part of clinical trials for stroke prevention among patients with NVAF, Compare and contrast evidence collected to date from real-world studies with data reported from clinical trials of DOACs to prevent stroke among patients with NVAF, Apply evidence from real-world studies and clinical trials of DOACs in patients with NVAF

    • 29分
    • video
    Milind Javle, MD - Enhancing Standards of Care for Patients With Biliary Tract Cancers: A Graphical Guide to Integrating a New Lineup of Targeted Therapies Into Practice

    Milind Javle, MD - Enhancing Standards of Care for Patients With Biliary Tract Cancers: A Graphical Guide to Integrating a New Lineup of Targeted Therapies Into Practice

    Go online to PeerView.com/GZS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gastrointestinal oncology provides an update on targeted therapies for patients with biliary tract cancers. Upon completion of this activity, participants should be better able to: Review the rationale of newly discovered targets, such as multikinase tumor pathways, NTRK gene fusions, and FGFR translocations, for biliary tract cancers, Appraise emerging efficacy and safety evidence on the use of novel targeted agents, including multikinase, TRK, and FGFR inhibitors, in patients with biliary tract cancers, Incorporate novel targeted agents safely and effectively into treatment plans for biliary tract cancers, including in the context of a clinical trial

    • 23分
    • video
    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

    • 1 時間12分

科学のトップPodcast

他のリスナーはこちらのサブスクリプションにも登録しています